Great Point Partners acquires Axiom Real-Time Metrics

Great Point Partners has completed a growth recapitalization of Axiom Real-Time Metrics. Financial terms were not disclosed.

Founded in 2001 by CEO Andrew Schachter, Toronto based Axiom Real-Time Metrics is a leading provider of unified eClinical solutions and services that are used to enhance the efficiency of Phase I, II and III clinical trials and observational studies.

Founded in 2003, Greenwich, Connecticut based Great Point Partners manage two separate and complementary investment strategies – lower middle market growth buyout funds investing in private health care companies and a hedge fund investing in public life sciences companies. GPP is currently making new private equity investments from GPP III, which has committed capital of US $280 million.

photo credit: Axiom Real-Time Metrics

News Release

Great Point Partners Completes Growth Equity Investment in Axiom Real-Time Metrics

May 8, 2019

GREENWICH, CT and TORONTO, CANADA – Great Point Partners (“GPP”) today announced a growth recapitalization of Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services that are used to enhance the efficiency of Phase I, II and III clinical trials and observational studies. Axiom is a leading e-clinical technology company that focuses on Electronic Data Capture (“EDC”), Data Management (“DM”), Clinical Trial Management Systems (“CTMS”), Randomization (“IWRS”), Electronic Patient Reported Outcomes (“ePRO”) and other technology and service solutions for biotechnology and pharmaceutical sponsors conducting clinical trials. Founded in 2001 and based in Toronto, Canada, the Company will leverage this funding to scale its technology system and superior customer service.

“From the beginning of our conversation when they proactively approached us about a partnership, Great Point demonstrated its expertise in the clinical trial service needs of biotechnology and pharmaceutical companies, Axiom’s core customer base. Their market knowledge and the depth of their experience investing in pharmaceutical services companies made them an ideal partner for Axiom as we enter our next phase of growth. GPP’s investment will allow Axiom to increase the level of customer service and add additional technology solutions and services,” said Andrew Schachter, Founder and CEO of Axiom.

“We are excited to partner with the Axiom team and help them execute an accelerated growth plan,” said Noah Rhodes, Managing Director at Great Point Partners. “Andrew and his team have built an impressive business that has been growing at 56% per year over the last six years. We look forward to introducing Andrew to the biotechnology CEOs in our network, all of whom are either current or potential customers for Axiom’s products and services.”

“Our work in the trenches alongside drug developers over the last decade has proven that there is a huge need for Axiom’s solutions. This need is reflected in their explosive growth and superb customer satisfaction reported to us by the CEOs who are their customers,” said Eddie Hjerpe, Senior Associate at Great Point Partners.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.6 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has committed capital of $280 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $280 million in committed capital) and public equity funds (BMVF, approximately $1.1 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Axiom Real-Time Metrics

Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study. Services include: Data Management, Data Analytics, Biostatistics and Pharmacovigilance. Axiom’s eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and more than 15 modules. Axiom serves as the Connected Hub for your entire clinical study data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting. For more information, please visit http://www.axiommetrics.com/.

Ted Liu

Ted Liu, M.Sc. (Mining, Queen's), MBA (Finance, Toronto), is the Editor of Private Capital Journal, CanadaMetals.ca, TechWire.ca, and the former Editor of Canadian Private Equity. Ted has been passionately tracking Canadian private capital industry since 1992, having most recently served as Research Director for The Canadian Venture Capital and Private Equity Association (CVCA).

Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.